Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.
Read the full articleYou might also wanna read
Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030
Viking Therapeutics (NASDAQ: VKTX) is positioning itself as a challenger in the obesity drug market, competing directly against industry tit
Celltrion's High-Margin Follow-On Products Expand Share in Europe
Celltrion's high-margin follow-on biosimilars are expanding their share across Europe, with Omlyclo reaching 16% and Vegzelma and Yuflyma ho
Novo Nordisk moves to launch Wegovy tablet in China
A race over obesity treatments is heating up in China, as global pharmaceutical giants compete to dominate the fast-growing market for weigh
Bayer sells stake in contraceptives business to Apollo in €3bn financing deal
Sale will help German pharmaceuticals group to bolster its balance sheet after years of litigation over Roundup weedkiller
Novo Nordisk loses global market lead to Eli Lilly outside the US
Novo Nordisk presses nu på endnu en afgørende flanke. Nye tal viser, at den danske medicinalgigant har mistet sit historiske forspring og ta
finans.dk·1mo ago
Novo Nordisk (NYSE: NVO) Stock Price Could Be Trading At A 48% Discount As Medicare Expands GLP-1 Coverage
Novo Nordisk (NYSE: NVO) has shed 32.7% of its value over the past three years, yet multiple valuation frameworks suggest the shares may be
Comments
Sign in to join the conversation.
No comments yet. Be the first.